Inhibition of WNT signaling by G007-LK, pyrvinium, or salinomycin prevents the clinical features of sclGVHD in the LP/J (H-2^b) → C57BL/6 (H-2^b) model. (A) Preventive treatment with G007-LK, pyrvinium, or salinomycin reduced weight loss after alloBMT and resulted in higher body weight (left panel). The clinical composite score for cutaneous cGVHD was lower in mice treated with G007-LK, pyrvinium, or salinomycin compared with vehicle-treated mice (right panel). (B) Representative trichrome-stained images of the skin of sclGVHD mice (original magnification ×100). WNT inhibitors prevented the histological changes in the dermis in experimental sclGVHD. (C) WNT inhibitors reduced dermal thickening, decreased the hydroxyproline content of the skin, and diminished the differentiation of resting fibroblasts into myofibroblasts compared with vehicle-treated mice with allogeneic transplantation. (D) Representative lung sections (original magnification ×200; Sirius Red stain). (E) Fibrotic area, hydroxyproline content, and myofibroblast counts of murine lung (n = 6 mice per group). *P < .5; **P < .05; ***P < .01.